{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:06:45Z","timestamp":1793898405403,"version":"4.8.0"},"reference-count":36,"publisher":"Walter de Gruyter GmbH","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hemophilia A and B are X-linked hemorrhagic disorders, characterized by low\/dysfunctional factor (F)VIII or FIX, respectively. The history of hemophilia treatment has evolved remarkably over time from the introduction of cryoprecipitate in the 1960s to plasma-derived factors in the 1970s. The 1980s brought a tragic chapter, as many plasma-derived products were contaminated with blood-borne viruses. In response to ongoing safety concerns, recombinant factors were developed in the 1990s. However, coagulation factors had a relatively short half-life upon infusion. As technology progressed, extended half-life factors were introduced in the 2010s. More recently, the development of non-transfusional therapies such as emicizumab has revolutionized prophylaxis. Additionally, gene therapy is emerging as a potentially curative approach. Despite these advances, discrepancies in laboratory assays have emerged as a significant challenge. Treatments employing extended half-life products and\/or gene therapy, may yield variable results depending on the type of assays used, typically one-stage clotting vs. chromogenic assays. These discrepancies can lead to confusion in monitoring factor levels and assessing treatment outcome. This article aims to review the current situation on results discrepancies recorded when measuring post infusion extended half-life factors with different methods and to provide guidance on options that may be adopted to minimize discrepancies.<\/jats:p>","DOI":"10.1515\/cclm-2026-0042","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T15:58:46Z","timestamp":1772553526000},"page":"1751-1758","source":"Crossref","is-referenced-by-count":1,"title":["Discrepancies of results for post infusion levels of extended half-life factor VIII\/IX concentrates\u00a0\u2013\u00a0a cause of concern, awaiting for solution"],"prefix":"10.1515","volume":"64","author":[{"given":"Armando","family":"Tripodi","sequence":"first","affiliation":[{"name":"IRCCS Ca\u2019 Granda Maggiore Hospital Foundation, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center , Milan , Italy"},{"name":"Fondazione Luigi Villa , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Novembrino","sequence":"additional","affiliation":[{"name":"IRCCS Ca\u2019 Granda Maggiore Hospital Foundation, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[{"name":"IRCCS Ca\u2019 Granda Maggiore Hospital Foundation, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center , Milan , Italy"},{"name":"Department of Pathophysiology and Transplantation , Universit\u00e0 degli Studi di Milan , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"2026070213034362638_j_cclm-2026-0042_ref_001","doi-asserted-by":"crossref","unstructured":"Peyvandi, F, Garagiola, I, Young, G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet 2016;388:187\u201397. https:\/\/doi.org\/10.1016\/s0140-6736(15)01123-x.","DOI":"10.1016\/S0140-6736(15)01123-X"},{"key":"2026070213034362638_j_cclm-2026-0042_ref_002","doi-asserted-by":"crossref","unstructured":"Mannucci, PM. Hemophilia treatment innovation: 50\u00a0years of progress and more to come. J\u00a0Thromb Haemostasis 2023;21:403\u201312. https:\/\/doi.org\/10.1016\/j.jtha.2022.12.029.","DOI":"10.1016\/j.jtha.2022.12.029"},{"key":"2026070213034362638_j_cclm-2026-0042_ref_003","doi-asserted-by":"crossref","unstructured":"Kitchen, S, Tiefenbacher, S, Gosselin, R. Factor activity assays for monitoring extended half-life FVIII and factor IX replacement therapies. Semin Thromb Hemost 2017;43:331\u20137. https:\/\/doi.org\/10.1055\/s-0037-1598058.","DOI":"10.1055\/s-0037-1598058"},{"key":"2026070213034362638_j_cclm-2026-0042_ref_004","doi-asserted-by":"crossref","unstructured":"Peyvandi, F, Garagiola, I. Clinical advances in gene therapy updates on clinical trials of gene therapy in haemophilia. Haemophilia 2019;25:738\u201346. https:\/\/doi.org\/10.1111\/hae.13816.","DOI":"10.1111\/hae.13816"},{"key":"2026070213034362638_j_cclm-2026-0042_ref_005","doi-asserted-by":"crossref","unstructured":"Wynn, TT, Gumuscu, B. Potential role of a new PEGylated recombinant factor VIII for hemophilia A. J\u00a0Blood Med 2016;7:121\u20138. https:\/\/doi.org\/10.2147\/jbm.s82457.","DOI":"10.2147\/JBM.S82457"},{"key":"2026070213034362638_j_cclm-2026-0042_ref_006","doi-asserted-by":"crossref","unstructured":"Pipe, SW. New therapies for hemophilia. Hematology Am Soc Hematol Educ Program 2016;2016:650\u20136. https:\/\/doi.org\/10.1182\/asheducation-2016.1.650.","DOI":"10.1182\/asheducation-2016.1.650"},{"key":"2026070213034362638_j_cclm-2026-0042_ref_007","doi-asserted-by":"crossref","unstructured":"Franchini, M, Mannucci, PM. The more recent history of hemophilia treatment. Semin Thromb Hemost 2022;48:904\u201310. https:\/\/doi.org\/10.1055\/s-0042-1756188.","DOI":"10.1055\/s-0042-1756188"},{"key":"2026070213034362638_j_cclm-2026-0042_ref_008","doi-asserted-by":"crossref","unstructured":"Konkle, BA, Shapiro, AD, Quon, DV, Staber, JM, Kulkarni, R, Ragni, MV, et al.. BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A. N\u00a0Engl J Med 2020;383:1018\u201327. https:\/\/doi.org\/10.1056\/nejmoa2002699.","DOI":"10.1056\/NEJMoa2002699"},{"key":"2026070213034362638_j_cclm-2026-0042_ref_009","doi-asserted-by":"crossref","unstructured":"Mahlangu, J, Kuliczkowski, K, Karim, FA, Stasyshyn, O, Kosinova, MV, Lepatan, LM, et al.. Efficacy and safety of rVIII-SingleChain: results of a phase 1\/3 multicenter clinical trial in severe hemophilia A. Blood 2016;128:630\u20137. https:\/\/doi.org\/10.1182\/blood-2016-01-687434.","DOI":"10.1182\/blood-2016-01-687434"},{"key":"2026070213034362638_j_cclm-2026-0042_ref_010","doi-asserted-by":"crossref","unstructured":"Tripodi, A, Chantarangkul, V, Novembrino, C, Peyvandi, F. Advances in the treatment of hemophilia: implications for laboratory testing. Clin Chem 2019;65:254\u201362. https:\/\/doi.org\/10.1373\/clinchem.2017.284356.","DOI":"10.1373\/clinchem.2017.284356"},{"key":"2026070213034362638_j_cclm-2026-0042_ref_011","doi-asserted-by":"crossref","unstructured":"Carcao, M, Zak, M, Abdul Karim, F, Hanabusa, H, Kearney, S, Lu, MY, et al.. Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial. J\u00a0Thromb Haemostasis 2016;14:1521\u20139. https:\/\/doi.org\/10.1111\/jth.13360.","DOI":"10.1111\/jth.13360"},{"key":"2026070213034362638_j_cclm-2026-0042_ref_012","doi-asserted-by":"crossref","unstructured":"Ezban, M, Hermit, MB, Persson, E. FIXing postinfusion monitoring: assay experiences with N9-GP (nonacog beta pegol; Refixia\u00ae; Rebinyn\u00ae). Haemophilia 2019;25:154\u201361. https:\/\/doi.org\/10.1111\/hae.13671.","DOI":"10.1111\/hae.13671"},{"key":"2026070213034362638_j_cclm-2026-0042_ref_013","doi-asserted-by":"crossref","unstructured":"Ros\u00e9n, P, Ros\u00e9n, S, Ezban, M, Persson, E. Overestimation of N-glycoPEGylated factor IX activity in a one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX. J\u00a0Thromb Haemostasis 2016;14:1420\u20137. https:\/\/doi.org\/10.1111\/jth.13359.","DOI":"10.1111\/jth.13359"},{"key":"2026070213034362638_j_cclm-2026-0042_ref_014","doi-asserted-by":"crossref","unstructured":"Tiefenbacher, S, Bohra, R, Amiral, J, Bowyer, A, Kitchen, S, Lochu, A, et al.. Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol. J\u00a0Thromb Haemostasis 2017;15:1901\u201312. https:\/\/doi.org\/10.1111\/jth.13787.","DOI":"10.1111\/jth.13787"},{"key":"2026070213034362638_j_cclm-2026-0042_ref_015","doi-asserted-by":"crossref","unstructured":"St Ledger, K, Feussner, A, Kalina, U, Horn, C, Metzner, HJ, Bensen-Kennedy, D, et al.. International comparative field study evaluating the assay performance of AFSTYLA in plasma samples at clinical hemostasis laboratories. J\u00a0Thromb Haemostasis 2018;16:555\u201364. https:\/\/doi.org\/10.1111\/jth.13932.","DOI":"10.1111\/jth.13932"},{"key":"2026070213034362638_j_cclm-2026-0042_ref_016","doi-asserted-by":"crossref","unstructured":"Bowyer, A, Key, N, Dalton, D, Kitchen, S, Makris, M. The coagulation laboratory monitoring of Afstyla single-chain FVIII concentrate. Haemophilia 2017;23:e469\u201370. https:\/\/doi.org\/10.1111\/hae.13290.","DOI":"10.1111\/hae.13290"},{"key":"2026070213034362638_j_cclm-2026-0042_ref_017","unstructured":"UK NEQAS ECAT Efanesoctocog alfa exercise 2024 participants report. https:\/\/www.neqascoag.org\/. [Accessed Sep 2025]."},{"key":"2026070213034362638_j_cclm-2026-0042_ref_018","doi-asserted-by":"crossref","unstructured":"Pipe, S, Sadeghi-Khomami, A, Konkle, BA, Kitchen, S, Negrier, C, Liu, M, et al.. A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratories. Haemophilia 2024;30:214\u201323. https:\/\/doi.org\/10.1111\/hae.14831.","DOI":"10.1111\/hae.14831"},{"key":"2026070213034362638_j_cclm-2026-0042_ref_019","doi-asserted-by":"crossref","unstructured":"Konkle, BA, Stasyshyn, O, Chowdary, P, Bevan, DH, Mant, T, Shima, M, et al.. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood 2015;126:1078\u201385. https:\/\/doi.org\/10.1182\/blood-2015-03-630897.","DOI":"10.1182\/blood-2015-03-630897"},{"key":"2026070213034362638_j_cclm-2026-0042_ref_020","doi-asserted-by":"crossref","unstructured":"Turecek, PL, Romeder-Finger, S, Apostol, C, Bauer, A, Crocker-Buqu\u00e9, A, Burger, DA, et al.. A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII: c activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE. Haemophilia 2016;22:957\u201365. https:\/\/doi.org\/10.1111\/hae.13001.","DOI":"10.1111\/hae.13001"},{"key":"2026070213034362638_j_cclm-2026-0042_ref_021","doi-asserted-by":"crossref","unstructured":"Ternisien, C, Lasne, D, Grand, F, Harzallah, I, Jeanpierre, E, Repesse, Y, French study group on laboratory management of bleeding disorders (BIMHO Group-GFHT), et al.. Impact of aPTT reagents on measurement of a PEGylated recombinant FVIII (Adynovi\u00ae\/Adynovate\u00ae): a French multicentric field assay study. Int J Lab Hematol 2022;44:e55\u20139. https:\/\/doi.org\/10.1111\/ijlh.13707.","DOI":"10.1111\/ijlh.13707"},{"key":"2026070213034362638_j_cclm-2026-0042_ref_022","doi-asserted-by":"crossref","unstructured":"Bulla, O, Poncet, A, Alberio, L, Asmis, LM, G\u00e4hler, A, Graf, L, et al.. Impact of a product-specific reference standard for the measurement of a PEGylated rFVIII activity: the Swiss multicentre field study. Haemophilia 2017;23:e335\u20139. https:\/\/doi.org\/10.1111\/hae.13250.","DOI":"10.1111\/hae.13250"},{"key":"2026070213034362638_j_cclm-2026-0042_ref_023","doi-asserted-by":"crossref","unstructured":"Rosen, S, Tiefenbacher, S, Robinson, M, Huang, M, Srimani, J, Mackenzie, D, et al.. Activity of transgene-produced B-domain-deleted factor VIII in human plasma following AAV5 gene therapy. Blood 2020;136:2524\u201334. https:\/\/doi.org\/10.1182\/blood.2020005683.","DOI":"10.1182\/blood.2020005683"},{"key":"2026070213034362638_j_cclm-2026-0042_ref_024","doi-asserted-by":"crossref","unstructured":"Foley, JH, Shehu, E, Riddell, A, Gray, E, Goodale, A, Yu, IM, et al.. Differences in wild-type- and R338L-tenase complex formation are at the root of R338L-factor IX assay discrepancies. Blood Adv 2023;7:458\u201367. https:\/\/doi.org\/10.1182\/bloodadvances.2022007435.","DOI":"10.1182\/bloodadvances.2022007435"},{"key":"2026070213034362638_j_cclm-2026-0042_ref_025","doi-asserted-by":"crossref","unstructured":"Raut, S, Hubbard, AR. International reference standards in coagulation. Biologicals 2010;38:423\u20139. https:\/\/doi.org\/10.1016\/j.biologicals.2010.02.009.","DOI":"10.1016\/j.biologicals.2010.02.009"},{"key":"2026070213034362638_j_cclm-2026-0042_ref_026","doi-asserted-by":"crossref","unstructured":"Tripodi, A, Garagiola, I, Bitto, N, La Mura, V, Peyvandi, F. Gene therapy for hemophilia. Opportunities and challenges for the clinical laboratory. Clin Chem 2025;71:1024\u201335. https:\/\/doi.org\/10.1093\/clinchem\/hvaf085.","DOI":"10.1093\/clinchem\/hvaf085"},{"key":"2026070213034362638_j_cclm-2026-0042_ref_027","doi-asserted-by":"crossref","unstructured":"Robinson, MM, George, LA, Carr, ME, Samelson-Jones, BJ, Arruda, VR, Murphy, JE, et al.. Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX-Padua. J\u00a0Thromb Haemostasis 2021;19:1212\u20138. https:\/\/doi.org\/10.1111\/jth.15281.","DOI":"10.1111\/jth.15281"},{"key":"2026070213034362638_j_cclm-2026-0042_ref_028","doi-asserted-by":"crossref","unstructured":"Gray, E, Kitchen, S, Bowyer, A, Chowdary, P, Jenkins, PV, Murphy, P, et al.. Laboratory measurement of factor replacement therapies in the treatment of congenital haemophilia: a United\u00a0Kingdom haemophilia centre doctors\u2019 organisation guideline. Haemophilia 2020;26:6\u201316. https:\/\/doi.org\/10.1111\/hae.13907.","DOI":"10.1111\/hae.13907"},{"key":"2026070213034362638_j_cclm-2026-0042_ref_029","doi-asserted-by":"crossref","unstructured":"Kitchen, S, Bowyer, A, Lowe, A, Jennings, I, Walker, ID. External quality assessment for one-stage and chromogenic factor IX assays in samples containing Alprolix (rFIXFc) or Idelvion (rIX-FP) and evidence that UK national external quality assessment scheme for blood coagulation samples are commutable with patient samples. Int J Lab Hematol 2022;44:619\u201325. https:\/\/doi.org\/10.1111\/ijlh.13795.","DOI":"10.1111\/ijlh.13795"},{"key":"2026070213034362638_j_cclm-2026-0042_ref_030","unstructured":"WFH Guidelines for the Management of Hemophilia, 3rd ed. www. chrome- extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www1.wfh.org\/publications\/files\/pdf-1863.pdf. [Accessed Sep 2025]."},{"key":"2026070213034362638_j_cclm-2026-0042_ref_031","doi-asserted-by":"crossref","unstructured":"Jacquemin, M, Vodolazkaia, A, Toelen, J, Schoeters, J, Van Horenbeeck, I, Vanlinthout, I, et al.. Measurement of B-domain-deleted ReFacto AF activity with a product-specific standard is affected by choice of reagent and patient-specific factors. Haemophilia 2018;24:675\u201382. https:\/\/doi.org\/10.1111\/hae.13123.","DOI":"10.1111\/hae.13123"},{"key":"2026070213034362638_j_cclm-2026-0042_ref_032","doi-asserted-by":"crossref","unstructured":"Grand, F, Blanc-Jouvan, F, Mourey, G, Ryman, A, Eschwege, V, Brionne-Fran\u00e7ois, M, et al.. Drug-specific calibration: a solution to reagent variability in extended half-life factor IX activity measurements. Haemophilia 2025;31:1307\u201314. https:\/\/doi.org\/10.1111\/hae.70115.","DOI":"10.1111\/hae.70115"},{"key":"2026070213034362638_j_cclm-2026-0042_ref_033","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez, P, Arrieta, MV, Detarsio, GA, Raviola, MP. Performance of a drug-specific calibration curve for monitoring treatment with albutrepenonacog alfa: a multicenter study in Argentina. Int J Lab Hematol 2025;47:713\u20139. https:\/\/doi.org\/10.1111\/ijlh.14469.","DOI":"10.1111\/ijlh.14469"},{"key":"2026070213034362638_j_cclm-2026-0042_ref_034","doi-asserted-by":"crossref","unstructured":"Bowyer, A, Kitchen, S. Monitoring ultralong half-life recombinant factor VIII: a product-specific calibrator is urgently needed to enable accurate measurement in all patients. J\u00a0Thromb Haemostasis 2025;23:1480\u20132. https:\/\/doi.org\/10.1016\/j.jtha.2025.01.024.","DOI":"10.1016\/j.jtha.2025.01.024"},{"key":"2026070213034362638_j_cclm-2026-0042_ref_035","doi-asserted-by":"crossref","unstructured":"Tripodi, A. Thrombin generation assay and its application in the clinical laboratory. Clin Chem 2016;62:699\u2013707. https:\/\/doi.org\/10.1373\/clinchem.2015.248625.","DOI":"10.1373\/clinchem.2015.248625"},{"key":"2026070213034362638_j_cclm-2026-0042_ref_036","doi-asserted-by":"crossref","unstructured":"Caspary, L, Shaw, JR, Stalder, O, Brodard, J, Angelillo-Scherrer, A, Vrotniakaite-Bajerciene, K. Clinical utility of thrombin generation using ST-Genesia\u00ae in patients with hereditary and acquired thrombophilia: a cross-sectional study. Thromb Res 2025;254:109454. https:\/\/doi.org\/10.1016\/j.thromres.2025.109454.","DOI":"10.1016\/j.thromres.2025.109454"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-0042\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-0042\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:04:07Z","timestamp":1783004647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-0042\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":36,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,3,20]]},"published-print":{"date-parts":[[2026,7,24]]}},"alternative-id":["10.1515\/cclm-2026-0042"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2026-0042","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]}}}